These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 29581079)

  • 1. Thiazolidinediones and Risk of Atrial Fibrillation Among Patients with Diabetes and Coronary Disease.
    Pallisgaard JL; Brooks MM; Chaitman BR; Boothroyd DB; Perez M; Hlatky MA;
    Am J Med; 2018 Jul; 131(7):805-812. PubMed ID: 29581079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
    Bach RG; Brooks MM; Lombardero M; Genuth S; Donner TW; Garber A; Kennedy L; Monrad ES; Pop-Busui R; Kelsey SF; Frye RL;
    Circulation; 2013 Aug; 128(8):785-94. PubMed ID: 23857320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Revascularization in patients with type 2 diabetes and coronary artery disease: BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) Study Group].
    Störk S; Ertl G; Nitschmann S
    Internist (Berl); 2010 May; 51(5):674-6. PubMed ID: 20352177
    [No Abstract]   [Full Text] [Related]  

  • 4. Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
    Sobel BE; Hardison RM; Genuth S; Brooks MM; McBane RD; Schneider DJ; Pratley RE; Huber K; Wolk R; Krishnaswami A; Frye RL;
    Circulation; 2011 Aug; 124(6):695-703. PubMed ID: 21768545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial of therapies for type 2 diabetes and coronary artery disease.
    ; Frye RL; August P; Brooks MM; Hardison RM; Kelsey SF; MacGregor JM; Orchard TJ; Chaitman BR; Genuth SM; Goldberg SH; Hlatky MA; Jones TL; Molitch ME; Nesto RW; Sako EY; Sobel BE
    N Engl J Med; 2009 Jun; 360(24):2503-15. PubMed ID: 19502645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DPP4i, thiazolidinediones, or insulin and risks of cancer in patients with type 2 diabetes mellitus on metformin-sulfonylurea dual therapy with inadequate control.
    Wong CKH; Man KKC; Chan EWY; Wu T; Tse ETY; Wong ICK; Lam CLK
    BMJ Open Diabetes Res Care; 2020 Jun; 8(1):. PubMed ID: 32532851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The BARI 2D study: a randomised trial of therapies for type 2 diabetes and coronary artery disease.
    Rutter MK; Nesto RW
    Diab Vasc Dis Res; 2010 Jan; 7(1):69-72. PubMed ID: 20368235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gender-specific effects of oral hypoglycaemic agents on cancer risk in type 2 diabetes mellitus.
    Sun GE; Wells BJ; Yip K; Zimmerman R; Raghavan D; Kattan MW; Kashyap SR
    Diabetes Obes Metab; 2014 Mar; 16(3):276-83. PubMed ID: 24199848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antihyperglycemic drugs use and new-onset atrial fibrillation in elderly patients.
    Chen HY; Yang FY; Jong GP; Liou YS
    Eur J Clin Invest; 2017 May; 47(5):388-393. PubMed ID: 28369870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihyperglycemic drugs use and new-onset atrial fibrillation: A population-based nested case control study.
    Liou YS; Yang FY; Chen HY; Jong GP
    PLoS One; 2018; 13(8):e0197245. PubMed ID: 30161122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased Hazard of Myocardial Infarction With Insulin-Provision Therapy in Actively Smoking Patients With Diabetes Mellitus and Stable Ischemic Heart Disease: The BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) Trial.
    Khan AA; Chung MJ; Novak E; Brown DL
    J Am Heart Assoc; 2017 Sep; 6(9):. PubMed ID: 28903941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coronary heart disease outcomes in patients receiving antidiabetic agents.
    McAfee AT; Koro C; Landon J; Ziyadeh N; Walker AM
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):711-25. PubMed ID: 17551989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Favorable effects of insulin sensitizers pertinent to peripheral arterial disease in type 2 diabetes: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial.
    Althouse AD; Abbott JD; Sutton-Tyrrell K; Forker AD; Lombardero MS; Buitrón LV; Pena-Sing I; Tardif JC; Brooks MM;
    Diabetes Care; 2013 Oct; 36(10):3269-75. PubMed ID: 23735723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
    Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
    PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thiazolidinediones and reduced risk of incident bacterial abscess in adults with type 2 diabetes: A population-based cohort study.
    Wang JL; Dong YH; Ko WC; Chang CH; Wu LC; Chuang LM; Chen PC
    Diabetes Obes Metab; 2018 Dec; 20(12):2811-2820. PubMed ID: 29974616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to letter regarding article, "rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial".
    Bach RG; Brooks MM; Lombardero M; Genuth S; Donner TW; Garber A; Kennedy L; Monrad ES; Pop-Busui R; Kelsey SF; Frye RL;
    Circulation; 2014 Apr; 129(16):e460-1. PubMed ID: 24753557
    [No Abstract]   [Full Text] [Related]  

  • 17. Relation of severe coronary artery narrowing to insulin or thiazolidinedione use in patients with type 2 diabetes mellitus (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes Study).
    Pop-Busui R; Lombardero M; Lavis V; Forker A; Green J; Korytkowski M; Sobel BE; Jones TL;
    Am J Cardiol; 2009 Jul; 104(1):52-8. PubMed ID: 19576321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
    Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S
    Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: A large database study from the Cleveland Clinic.
    Kannan S; Pantalone KM; Matsuda S; Wells BJ; Karafa M; Zimmerman RS
    J Diabetes; 2016 Mar; 8(2):279-85. PubMed ID: 25929426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study.
    Seong JM; Choi NK; Shin JY; Chang Y; Kim YJ; Lee J; Kim JY; Park BJ
    PLoS One; 2015; 10(5):e0124287. PubMed ID: 25992614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.